| HOME >> BIOLOGY >> TECHNOLOGY |
SARASOTA, Fla., Oct. 24 /PRNewswire-FirstCall/ -- CPC of America, Inc. (OTC Bulletin Board: CPCF), a company focused on developing therapeutic devices for use in endovascular procedures, announced today that it has entered into a manufacturing agreement with BC Tech. According to the agreement, BC Tech will manufacture the MedClose(TM) vascular closure system (VCS), a Class II extravascular puncture-closure device that may be used with a biological sealant for worldwide commercial application in diagnostic and interventional cardiovascular procedures. The Company aims to fill a global market need for a safe, reliable closure system that reduces time to hemostasis and allows for faster patient ambulation and, when necessary, wound re-access.
Under the terms of the agreement, BC Tech will be responsible for manufacturing the MedClose system for use in commercial applications to seal the femoral artery access site following cardiac and peripheral vascular catheterization procedures when approved. BC Tech will also build prototypes of larger caliber for potential use in percutaneous procedures. Initially, BC Tech will manufacture MedClose systems on a limited basis and does not expect to commence large scale manufacturing until the Company has obtained commercial application approvals.
With a state-of-the-art design and manufacturing facility in Santa Cruz, California, BC Tech is a worldwide approved ISO-certified medical and biotech device manufacturer with a device portfolio that includes clients such as Artemis, SurgRx(TM) and Aceuity.
"This agreement with BC Tech is a critical step toward bringing
MedClose(TM) to market," said Rod Shipman, chairman and chief executive
officer of CPC of America. "We look forward to working with BC Tech to
leverage its experience in the successful design, development, and
commercial manufacturing of medical devices. By building prototypes, BC
Tech also will assist us in our strategy to expand the potential
'/>"/>
| SOURCE CPC of America, Inc. Copyright©2008 PR Newswire. All rights reserved |